Skip to main content

Intratumoral 2141-V11 With Standard Therapy

2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

  • RegistryNCT07818018
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionAdvanced Esophageal, Gastric or GEJ Cancer
  • SponsorMemorial Sloan Kettering Cancer Center
How 2141-V11 worksNCT078180181 min

What the film says

Read the transcript

This trial is for adults with advanced esophageal, stomach, or gastroesophageal junction cancer who are already on first line treatment.

The idea: inject 2141-V11 directly into a tumor while patients continue standard immunotherapy, with or without 5-FU chemotherapy. 2141-V11 is an antibody that switches on CD40, a receptor that can help start an immune response.

The study looks first at safety.

This phase 1 and 2 study plans 30 patients. At Memorial Sloan Kettering Cancer Center in New York, Samuel Cytryn leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07818018

    Adults; advanced esophageal/gastric/GEJ adenocarcinoma on first-line therapy; Injected into tumor; continue anti-PD-1 with or without 5-FU; Antibody that activates CD40; Safety first (+1 more lines)

The drug

What is being tested.

2141-V11 is a recombinant fully humanized IgG1 monoclonal antibody directed against CD40, which activates the CD40 receptor.

5-FU will be administered as a continuous infusion over 48 hours

The study

How the trial runs.

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed esophageal, gastric, or gastroesophageal junction adenocarcinoma
  • Locally advanced unresectable or metastaticdisease at diagnosis
  • On first line systemic therapy including fluoropyrimidine + anti-PD-1 therapy for advanced GEA (e.g. FOLFOX + nivolumab) for a minimum of 3 months and no more than 9 months.
  • Platinum chemotherapy included in first line regimen has been discontinued or will be discontinued ≥2 weeks prior to first planned dose of 2141-V11
  • Patients in the safety lead-in cohort must be on 5-FU
  • Primary esophageal, gastric, or gastroesophageal junction tumor intact and visible at time of enrollment (within 1 month of 2141-V11 treatment initiation) on endoscopy

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.